In collaboration with the University of Perugia, our group previously showed that FTIR analysis is a valuable approach to identifying new specific chemical fingerprints of heart failure with preserved ejection fraction (HFpEF) (DOI: 10.1038/s41598-022-07390-2).
Recently, we took advantage of FTIR analysis to assess the hypertensive damage in renal tissue before and after treatment with a new therapeutic agent, the cardiac hormone proANP31-67. We identified specific spectral markers associated with the structural changes in renal tissue following hypertension. Importantly, FTIR spectroscopy was able to detect the beneficial effect of chronic administration of proANP31-67, demonstrating the therapeutic effects of this cardiac hormone in the treatment of renal impairment secondary to hypertension and HFpEF. Our findings indicate that FTIR is an innovative approach that opens new avenues in the diagnosis of cardiac and renal disease and can provide valuable information on the mechanism of action of new treatments.
